A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

NCT06244316 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: rhNGF 5 μg/mL
DRUG: rhNGF 10 μg/mL
DRUG: Vehicle (Placebo solution)

Sponsor

Dompé Farmaceutici S.p.A